ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,699.83
-0.04%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Viracta Therapeutics Inc (VIRX)

  7. Viracta Therapeutics Inc (VIRX) Noticias

VIRX

Viracta Therapeutics (VIRX)

Viracta Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VIRX
FechaHoraFuenteTítuloSímboloCompañía
31/05/202415:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
29/05/202418:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
17/05/202415:05GlobeNewswire Inc.Viracta Therapeutics Announces New Employment Inducement GrantsNASDAQ:VIRXViracta Therapeutics Inc
16/05/202415:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
14/05/202406:00GlobeNewswire Inc.Viracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerNASDAQ:VIRXViracta Therapeutics Inc
09/05/202416:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRXViracta Therapeutics Inc
09/05/202415:05GlobeNewswire Inc.Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
07/05/202415:05GlobeNewswire Inc.Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:VIRXViracta Therapeutics Inc
15/04/202407:00GlobeNewswire Inc.Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaNASDAQ:VIRXViracta Therapeutics Inc
01/04/202407:30GlobeNewswire Inc.Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanNASDAQ:VIRXViracta Therapeutics Inc
07/03/202416:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRXViracta Therapeutics Inc
07/03/202415:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRXViracta Therapeutics Inc
07/03/202415:05GlobeNewswire Inc.Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
29/02/202407:00GlobeNewswire Inc.Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialNASDAQ:VIRXViracta Therapeutics Inc
27/02/202419:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIRXViracta Therapeutics Inc
13/02/202420:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VIRXViracta Therapeutics Inc
06/02/202415:05GlobeNewswire Inc.Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:VIRXViracta Therapeutics Inc
04/01/202407:00GlobeNewswire Inc.Viracta Therapeutics Provides Clinical Update and Outlook for 2024NASDAQ:VIRXViracta Therapeutics Inc
12/12/202307:00GlobeNewswire Inc.Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaNASDAQ:VIRXViracta Therapeutics Inc
04/12/202307:30GlobeNewswire Inc.Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNASDAQ:VIRXViracta Therapeutics Inc
09/11/202307:30GlobeNewswire Inc.Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
07/11/202315:15GlobeNewswire Inc.Viracta Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:VIRXViracta Therapeutics Inc
04/10/202306:00GlobeNewswire Inc.Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated CancersNASDAQ:VIRXViracta Therapeutics Inc
05/09/202308:00GlobeNewswire Inc.Viracta Therapeutics to Host R&D Day on October 4, 2023NASDAQ:VIRXViracta Therapeutics Inc
18/08/202315:05GlobeNewswire Inc.Viracta Therapeutics Announces New Employment Inducement GrantNASDAQ:VIRXViracta Therapeutics Inc
14/08/202307:00GlobeNewswire Inc.Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
08/08/202307:30GlobeNewswire Inc.Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) LymphomaNASDAQ:VIRXViracta Therapeutics Inc
07/08/202306:30GlobeNewswire Inc.Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical OfficerNASDAQ:VIRXViracta Therapeutics Inc
28/06/202307:00GlobeNewswire Inc.Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)NASDAQ:VIRXViracta Therapeutics Inc
09/06/202317:50Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VIRXViracta Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRX

Su Consulta Reciente

NYSE
AXP
American Express
NYSE
NKE
Nike
NYSE
MCD
McDonalds
CCOM
US500
US 500
NYSE
VZ
Verizon Communications
NYSE
MRK
Merck
PM
XAUUSD
Gold vs US Dollar
AMEX
XLV
Health Care Select Sector
NASDAQ
MSFT
Microsoft
COIN
SOLUSD
Solana
FX
USDMXN
US Dollar vs MXN
USOTC
BNPQY
BNP Paribas (QX)
AMEX
XLE
Energy Select Sector SPDR
NYSE
XOM
Exxon Mobil
NYSE
CVX
Chevron
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados